MedTrace Logo

Feasibility - Infinitome

NCT04563767 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2021-02-17

Study results available
· View outcomes & findings →

Summary

The Infinitome Program from Omniscient has the ability to identify abnormal brain networks or connectomes using resting state functional MRI (rs-fMRI). This technology, which visualizes brain networks in three dimensions, was originally developed to ensure neurosurgeons avoid inadvertently lesioning cognitively eloquent brain regions during surgical operations. The potential of Infinitome in identifying connectome dysfunction for neurodegenerative diseases such as Alzheimer's disease has yet to be explored. This diagnostic technique may play a critical role for identifying disease brain networks that may benefit from targeted interventions in clinical trials.

Conditions

  • Alzheimer Disease

Interventions

PROCEDURE

Infinitome

Added sequence of rs-fMRI.

Sponsors & Collaborators

  • HealthPartners Institute

    lead OTHER

Principal Investigators

  • Michael H Rosenbloom, MD · HealthPartners Neurology

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2020-10-13
Completion
2020-10-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04563767 on ClinicalTrials.gov